TVMR With the Innovalve System Trial - Pilot in Georgia (TWIST-PILOT-GE)

April 18, 2025 updated by: Edwards Lifesciences
Study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study is a multi-center, First-In-Human, prospective, single pilot study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Georgia
      • Tbilisi, Georgia
        • Tbilisi Heart and Vascular Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinically significant, symptomatic mitral regurgitation
  • High risk for open-heart surgery
  • Meets anatomical criteria

Exclusion Criteria:

  • Unsuitable anatomy
  • Patient is inoperable
  • EF<25%

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Innovalve TMVR System
MV replacement with Innovalve MR system
Device: Innovalve MR system
Innovalve MR system

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Absence of implant or delivery related serious adverse events at 30 days
Time Frame: 30 days
Absence of implant or delivery related serious adverse events
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Technical success
Time Frame: Procedure
i. Absence of procedural mortality; and ii. Successful access, delivery, and retrieval of the device delivery system; and iii. Successful deployment and correct positioning of the first intended device; and iv. Freedom from emergency surgery or reintervention related to the device or access procedure.
Procedure
Procedural success
Time Frame: 30 days

All of the following must be present:

I. Deployment of the device

II. Absence of major device or procedure related serious adverse events, including:

  1. Death
  2. Stroke
  3. Life-threatening bleeding (MVARC scale)
  4. Major vascular complications
  5. Major cardiac structural complications
  6. Stage 2 or 3 acute kidney injury (includes new dialysis)
  7. Myocardial infarction or coronary ischemia requiring PCI or CABG
  8. Severe hypotension, heart failure, or respiratory failure requiring intravenous pressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for 48 h.
  9. Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention
30 days
NYHA functional class
Time Frame: 30 days, 6, 1 year
30 days, 6, 1 year
Six-minute walk test
Time Frame: 30 days, 6, 1 year
30 days, 6, 1 year
Quality of life improvement (KCCQ-12) Kansas City Cardiomyopathy Questionnaire
Time Frame: 30 days, 6, 1 year
30 days, 6, 1 year
Reduction in Mitral Regurgitation grade
Time Frame: 30 days, 6, 1 year
30 days, 6, 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Edwards Lifesciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2021

Primary Completion (Actual)

January 1, 2025

Study Completion (Actual)

January 1, 2025

Study Registration Dates

First Submitted

December 22, 2022

First Submitted That Met QC Criteria

January 10, 2023

First Posted (Actual)

January 12, 2023

Study Record Updates

Last Update Posted (Actual)

April 23, 2025

Last Update Submitted That Met QC Criteria

April 18, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • INVL21-01-GE

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mitral Valve Regurgitation (Degenerative or Functional)

Clinical Trials on Innovalve MR system

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe